Partnering opportunity

First biomarker test for the diagnosis of osteoarthritis

Summary

A German university offers autoantibodies that improve the diagnosis of osteoarthritis. It is the first serum biomarker test in this context. Partners from the medical diagnostic industry are sought for license agreements as well as a technical cooperation agreement.

Partner sought

The university offers a license agreement to companies in the diagnostic sector (analysing blood) or companies offering supplies/ materials for blood analysis. The biomarker is in an early development stage and further patient trials need to be done. Hence the university also offers a technical cooperation agreement in order to develop the existing test into an operable routine test.

Description

Osteoarthritis (OA) is the most common degenerative disease of joints world-wide. About two-third of people over 65 years are affected, whereas the etiology is largely unclear. Currently, there is no causative therapy available, which is due to the complex pathomechanisms of arthrosis and also due to the lack of diagnostic biomarkers that allow monitoring of therapeutic success of drug candidates. Researchers of a German university have found that autoantibodies against the cartilage protein thrombospondin 4 (TSP-4) occur in the course of arthrosis. Rheumatoid arthritis is characterized by the presence of autoantibodies, but autoantibodies against TSP-4 have not yet been described for arthrosis. In addition to TSP-4, the researchers have found autoantibodies against the cartilage oligomeric matrix protein (COMP) and the C-type lectin domain family 3 member A (CLEC3A) in the course of OA, which may be used in a combined test together with TSP-4 in order to strengthen significance of diagnosis (Table 1). Thus the present invention is the first serum biomarker test that helps to support the clinical diagnosis of OA. The university offers a license agreement to companies in the medical diagnostic sector. The university also offers a technical cooperation agreement because the biomarker is in an early development stage and needs to be develeoped into an operable routine test.

Advantages and innovations

The present invention is the first serum biomarker test that helps to support the clinical diagnosis of OA and furthermore it may provide a tool that allows the monitoring of therapeutic success of drug candidates for the treatment of arthrosis.

Development stage

Field tested/evaluated

Intellectual Property Rights (IPR)

Patent(s) applied for but not yet granted


Register your interest

How it works

  • Tell us about yourself
  • We’ll discuss with you
  • We put the right partners in touch

EEN help you find the right partner, rather than you going it alone.

Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.

These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.

Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.

?What value does EEN add?
This is your pitch: remember to include your unique selling points (USP) and why someone would want to do business with you
Tell us why you are a good fit for this opportunity, and why you think you're the right people for this partnership
If there's anything additional, or commercially sensitive you'd like to know about this opportunity, please let us know

When you entered your email address above, we emailed you a code to verify you're human and have access to that account.

?What's this?

What next?

To finish up, we just need some extra details about you and your company